AUA 2025: Postoperative Adjuvant Treatment of HER2-Overexpressing Upper Tract Urothelial Carcinoma with Disitamab Vedotin and Toripalimab: A Real-World Retrospective Study
AUA 2025 HER2-overexpressing upper tract urothelial carcinoma, disitamab vedotin, toripalimab, Radical nephroureterectomy, surgery for urothelial carcinoma.